GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Almirall SA (FRA:E2Z) » Definitions » Loans Receivable

Almirall (FRA:E2Z) Loans Receivable : €0.0 Mil (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Almirall Loans Receivable?

Almirall's Loans Receivable for the quarter that ended in Mar. 2024 was €0.0 Mil.


Almirall Loans Receivable Historical Data

The historical data trend for Almirall's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Almirall Loans Receivable Chart

Almirall Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Almirall Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23 Mar24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Almirall Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Almirall Loans Receivable Related Terms

Thank you for viewing the detailed overview of Almirall's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Almirall (FRA:E2Z) Business Description

Traded in Other Exchanges
Address
Ronda General Mitre 151, Barcelona, ESP, 08022
Almirall SA is a Spain-based company engaged in development, manufacture, and selling pharmaceutical products across a range of therapeutic areas. It aims to provide treatments in areas of dermatology, respiratory, gastrointestinal, central nervous systems, and other specialties. The company operates in five segments: Sales of its own network, sales of licensees, Research and developments, Sales of Therapeutic dermatological products in the U.S., and Corporate management. The medical dermatology business in the Europe is the key driver of the company's operation. Other than Europe, the company also operates in the Americas, Asia, Africa, and Oceania through subsidiaries.

Almirall (FRA:E2Z) Headlines

No Headlines